Wikipedia

Methoxyetomidate

Methoxyetomidate
Clinical data
Other namesET-26; Moxetomidate
Identifiers
  • 2-methoxyethyl (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC15H18N2O3
Molar mass274.320 g·mol−1
3D model (JSmol)
  • [C@H](C)(N1C(C(OCCOC)=O)=CN=C1)C2=CC=CC=C2
  • InChI=InChI=1S/C15H18N2O3/c1-12(13-6-4-3-5-7-13)17-11-16-10-14(17)15(18)20-9-8-19-2/h3-7,10-12H,8-9H2,1-2H3/t12-/m1/s1
  • Key:JJSJTELMIQBHDE-GFCCVEGCSA-N

Methoxyetomidate is an investigational anesthetic agent being developed by Jinzhou Ahon Pharmaceutical Co., Ltd. It is a short-acting intravenous anesthetic that acts as a positive allosteric modulator of GABAA receptors.[1][2] As of 2024, methoxyetomidate is undergoing Phase 3 clinical trials for use in anesthesia.[3][1]

References

[edit]
  1. ^ a b "ET-26 Methoxyetomidate Hydrochloride Development Information". Synapse by Patsnap. Retrieved 2024-11-23.
  2. ^ Wang B, Chen S, Yang J, Yang L, Liu J, Zhang W (2017). "ET-26 hydrochloride (ET-26 HCl) has similar hemodynamic stability to that of etomidate in normal and uncontrolled hemorrhagic shock (UHS) rats". PLOS ONE. 12 (8) e0183439. Bibcode:2017PLoSO..1283439W. doi:10.1371/journal.pone.0183439. PMC 5557577. PMID 28813523.
  3. ^ "ET-26 Clinical Trials Overview". Synapse by Patsnap. Retrieved 2024-11-23.
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.